Is pharmacotherapy guideline concordance consistent across patients who received pragmatic treatment for major depressive disorder?

Pharmacotherapy guideline concordance for the treatment of major depressive disorder (MDD) is associated with improved symptom severity, but it is unclear whether such associations vary by patients' characteristics or their comorbidity burden. We sought to determine whether guideline concordance varied significantly by 1) sociodemographic characteristics or 2) comorbidity. This study evaluated 1,403 U.S. adults (67% female, 85% non-Hispanic/Latino White, mean age of 43 years) with non-psychotic MDD and complete data (n = 1,241/1,403). We used a guideline concordance algorithm (GCA-8) to measure pharmacotherapeutic concordance with the Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines and multivariable general linear and proportional odds models to examine associations between this GCA-8 score and patients' characteristics. Being male was significantly associated with higher guideline concordance, but guideline concordance did not vary significantly by any other sociodemographic characteristics. Similarly, no comorbidities examined by this study presented substantial evidence of associations with guideline concordance. Within this sample, the GCA-8 algorithm consistently measured the degree of guideline concordance across different patient types. This study suggests that guideline concordance for MDD pharmacotherapy, as measured by the GCA-8, does not significantly vary by the comorbidities or sociodemographic characteristics analysed in this study, except for patient-reported gender.